Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
2 "Tae-Seo Sohn"
Filter
Filter
Article type
Keywords
Publication year
Authors
Funded articles
Original Articles
Calcium & bone metabolism
Persistence with Denosumab in Male Osteoporosis Patients: A Real-World, Non-Interventional Multicenter Study
Chaiho Jeong, Jeongmin Lee, Jinyoung Kim, Jeonghoon Ha, Kwanhoon Jo, Yejee Lim, Mee Kyoung Kim, Hyuk-Sang Kwon, Tae-Seo Sohn, Ki-Ho Song, Moo Il Kang, Ki-Hyun Baek
Endocrinol Metab. 2023;38(2):260-268.   Published online April 27, 2023
DOI: https://doi.org/10.3803/EnM.2023.1663
  • 1,780 View
  • 111 Download
  • 1 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Persistence with denosumab in male patients has not been adequately investigated, although poor denosumab persistence is associated with a significant risk of rebound vertebral fractures.
Methods
We retrospectively evaluated 294 Korean male osteoporosis patients treated with denosumab at three medical centers and examined their persistence with four doses of denosumab injection over 24 months of treatment. Persistence was defined as the extent to which a patient adhered to denosumab treatment in terms of the prescribed interval and dose, with a permissible gap of 8 weeks. For patients who missed their scheduled treatment appointment(s) during the follow-up period (i.e., no-shows), Cox proportional regression analysis was conducted to explore the factors associated with poor adherence. Several factors were considered, such as age, prior anti-osteoporotic drug use, the treatment provider’s medical specialty, the proximity to the medical center, and financial burdens of treatment.
Results
Out of 294 male patients, 77 (26.2%) completed all four sequential rounds of the denosumab treatment. Out of 217 patients who did not complete the denosumab treatment, 138 (63.6%) missed the scheduled treatment(s). Missing treatment was significantly associated with age (odds ratio [OR], 1.03), prior bisphosphonate use (OR, 0.76), and prescription by non-endocrinologists (OR, 2.24). Denosumab was stopped in 44 (20.3%) patients due to medical errors, in 24 (11.1%) patients due to a T-score improvement over –2.5, and in five (2.3%) patients due to expected dental procedures.
Conclusion
Our study showed that only one-fourth of Korean male osteoporosis patients were fully adherent to 24 months of denosumab treatment.

Citations

Citations to this article as recorded by  
  • Denosumab

    Reactions Weekly.2023; 1963(1): 206.     CrossRef
Close layer
Clinical Study
Obesity and Hyperglycemia in Korean Men with Klinefelter Syndrome: The Korean Endocrine Society Registry
Seung Jin Han, Kyung-Soo Kim, Wonjin Kim, Jung Hee Kim, Yong-ho Lee, Ji Sun Nam, Ji A Seo, Bu Kyung Kim, Jihyun Lee, Jin Ook Chung, Min-Hee Kim, Tae-Seo Sohn, Han Seok Choi, Seong Bin Hong, Yoon-Sok Chung
Endocrinol Metab. 2016;31(4):598-603.   Published online December 20, 2016
DOI: https://doi.org/10.3803/EnM.2016.31.4.598
  • 5,304 View
  • 35 Download
  • 20 Web of Science
  • 18 Crossref
AbstractAbstract PDFPubReader   
Background

The aim of this study was to investigate the prevalence of obesity in Korean men with Klinefelter syndrome (KS) and the associated risk factors for obesity and hyperglycemia.

Methods

Data were collected retrospectively from medical records from 11 university hospitals in Korea between 1994 and 2014. Subjects aged ≥18 years with newly diagnosed KS were enrolled. The following parameters were recorded at baseline before treatment: chief complaint, height, weight, fasting glucose level, lipid panel, blood pressure, testosterone, luteinizing hormone, follicle-stimulating hormone, karyotyping patterns, and history of hypertension, diabetes, and dyslipidemia.

Results

Data were analyzed from 376 of 544 initially enrolled patients. The rate of the 47 XXY chromosomal pattern was 94.1%. The prevalence of obesity (body mass index ≥25 kg/m2) in Korean men with KS was 42.6%. The testosterone level was an independent risk factor for obesity and hyperglycemia.

Conclusion

Obesity is common in Korean men with KS. Hypogonadism in patients with KS was associated with obesity and hyperglycemia.

Citations

Citations to this article as recorded by  
  • A dual-center study of predictive factors for sperm retrieval through microdissection testicular sperm extraction and intracytoplasmic sperm injection outcomes in men with non-mosaic Klinefelter syndrome
    Jong Hyeun Baeck, Tae Jin Kim, Tae Heon Kim, Seung-Ryeol Lee, Dong Soo Park, Hwang Kwon, Ji Eun Shin, Dong Hyeon Lee, Young Dong Yu
    Investigative and Clinical Urology.2023; 64(1): 41.     CrossRef
  • Cardiorespiratory fitness in adolescents and young adults with Klinefelter syndrome – a pilot study
    Julia Spiekermann, Kathrin Sinningen, Beatrice Hanusch, Michaela Kleber, Michael M. Schündeln, Cordula Kiewert, Heide Siggelkow, Jakob Höppner, Corinna Grasemann
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Metabolic Profile in a Cohort of Young Sicilian Patients with Klinefelter’s Syndrome: The Role of Irisin
    Stefano Radellini, Valentina Guarnotta, Vincenzo Sciabica, Giuseppe Pizzolanti, Carla Giordano, Vito Angelo Giagulli
    International Journal of Endocrinology.2022; 2022: 1.     CrossRef
  • Metabolic and Nutritional Aspects in Paediatric Patients with Klinefelter Syndrome: A Narrative Review
    Chiara Mameli, Giulia Fiore, Arianna Sangiorgio, Marta Agostinelli, Giulia Zichichi, Gianvincenzo Zuccotti, Elvira Verduci
    Nutrients.2022; 14(10): 2107.     CrossRef
  • Klinefelter syndrome in an adolescent with severe obesity, insulin resistance, and hyperlipidemia, successfully treated with testosterone replacement therapy
    Shota Fukuhara, Jun Mori, Hisakazu Nakajima
    Clinical Pediatric Endocrinology.2021; 30(3): 127.     CrossRef
  • Glucose metabolic disorder in Klinefelter syndrome: a retrospective analysis in a single Chinese hospital and literature review
    Shixuan Liu, Tao Yuan, Shuoning Song, Shi Chen, Linjie Wang, Yong Fu, Yingyue Dong, Yan Tang, Weigang Zhao
    BMC Endocrine Disorders.2021;[Epub]     CrossRef
  • What Every Internist-Endocrinologist Should Know about Rare Genetic Syndromes in Order to Prevent Needless Diagnostics, Missed Diagnoses and Medical Complications: Five Years of ‘Internal Medicine for Rare Genetic Syndromes’
    Anna G. W. Rosenberg, Minke R. A. Pater, Karlijn Pellikaan, Kirsten Davidse, Anja A. Kattentidt-Mouravieva, Rogier Kersseboom, Anja G. Bos-Roubos, Agnies van Eeghen, José M. C. Veen, Jiske J. van der Meulen, Nina van Aalst-van Wieringen, Franciska M. E. H
    Journal of Clinical Medicine.2021; 10(22): 5457.     CrossRef
  • Klinefelter Syndrome and Diabetes
    Mark J. O’Connor, Emma A. Snyder, Frances J. Hayes
    Current Diabetes Reports.2019;[Epub]     CrossRef
  • Endocrine aspects of Klinefelter syndrome
    Adriana Herrera Lizarazo, Michelle McLoughlin, Maria G. Vogiatzi
    Current Opinion in Endocrinology, Diabetes & Obesity.2019; 26(1): 60.     CrossRef
  • Sex differences in metabolism and cardiometabolic disorders
    Karthickeyan Chella Krishnan, Margarete Mehrabian, Aldons J. Lusis
    Current Opinion in Lipidology.2018; 29(5): 404.     CrossRef
  • Klinefelter Syndrome: Integrating Genetics, Neuropsychology, and Endocrinology
    Claus H Gravholt, Simon Chang, Mikkel Wallentin, Jens Fedder, Philip Moore, Anne Skakkebæk
    Endocrine Reviews.2018; 39(4): 389.     CrossRef
  • Sex differences in obesity, lipid metabolism, and inflammation—A role for the sex chromosomes?
    Temeka Zore, Maria Palafox, Karen Reue
    Molecular Metabolism.2018; 15: 35.     CrossRef
  • Klinefelter syndrome, insulin resistance, metabolic syndrome, and diabetes: review of literature and clinical perspectives
    Andrea Salzano, Roberta D’Assante, Liam M. Heaney, Federica Monaco, Giuseppe Rengo, Pietro Valente, Daniela Pasquali, Eduardo Bossone, Daniele Gianfrilli, Andrea Lenzi, Antonio Cittadini, Alberto M. Marra, Raffaele Napoli
    Endocrine.2018; 61(2): 194.     CrossRef
  • Síndrome de Klinefelter y riesgo cardiovascular
    A. Yamaguchi, P. Knoblovits
    Hipertensión y Riesgo Vascular.2018; 35(4): 195.     CrossRef
  • Articles inEndocrinology and Metabolismin 2016
    Won-Young Lee
    Endocrinology and Metabolism.2017; 32(1): 62.     CrossRef
  • Sex differences in obesity: X chromosome dosage as a risk factor for increased food intake, adiposity and co-morbidities
    Karen Reue
    Physiology & Behavior.2017; 176: 174.     CrossRef
  • Klinefelter Syndrome with Morbid Obesity Before Bariatric Surgery: A Case Report
    Parisa Janmohammadi, Gholamreza Mohammadi-Farsani, Hana Arghavani, Mahmoud Arshad, Tayebeh Mokhber
    Journal of Minimally Invasive Surgical Sciences.2017;[Epub]     CrossRef
  • Klinefelter Syndrome and Metabolic Disorder
    Ji Cheol Bae
    Endocrinology and Metabolism.2016; 31(4): 535.     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism